Management of Molluscum Contagiosum in Immunocompetent Patients

Natural History and Indications for Active Treatment

Watchful waiting is appropriate for most immunocompetent patients because 70‑90 % of lesions resolve spontaneously within 6–12 months, although complete clearance may take up to 4 years in a minority. (moderate evidence) 1
Active treatment should be considered when lesions are located on cosmetically sensitive areas (e.g., face, hands), when the patient has underlying eczema, or when lesions are symptomatic (pain, itching, erythema). (moderate evidence) 1

Cryotherapy with liquid nitrogen provides efficacy comparable to 10 % potassium hydroxide in children, but it carries a risk of post‑inflammatory hyperpigmentation or, rarely, scarring; therefore it should be avoided in patients with darker skin types. (moderate evidence) 1
Curettage (including incision‑curettage or simple excision with cautery) effectively removes lesions, reduces viral load, and facilitates host immune clearance. (moderate evidence) 2
For athletes, lesions should be curetted or otherwise removed before participation in contact sports to prevent trauma and transmission. (expert consensus) 3

10 % potassium hydroxide is effective for cosmetically bothersome lesions or in patients with eczema and shows similar cure rates to cryotherapy in pediatric studies. (moderate evidence) 1
Cantharidin demonstrates effectiveness in open‑label and observational studies; however, a small randomized trial (n = 29) showed a non‑significant trend toward improvement over placebo, indicating limited high‑quality evidence. (low‑quality evidence) 1
Imiquimod has not demonstrated benefit over placebo in randomized controlled trials and therefore should not be used when evidence‑based efficacy is required. (high‑quality evidence) 1

Children with molluscum contagiosum may attend school immediately without exclusion, treatment, or activity restrictions, and routine classroom activities do not require covering of lesions. (expert consensus) 3
For contact sports, lesions should be removed before competition; solitary or localized lesions may be covered with a gas‑permeable membrane and tape if removal is not feasible. Covering is optional for physical‑education classes. (expert consensus) 3
When participating in swimming or other water activities, covering lesions prone to bleeding with a gas‑permeable membrane and tape is advised by some experts, although it is not universally required. (expert consensus) 3

Do not prescribe imiquimod expecting therapeutic benefit; randomized trials have shown no advantage over placebo. (high‑quality evidence) 1
Avoid cryotherapy in patients with darker skin tones because of the heightened risk of post‑inflammatory hyperpigmentation. (moderate evidence) 1
When treating multiple lesions, ensure nascent (early‑stage) lesions are identified and addressed to reduce the risk of recurrence. (moderate evidence) 2
In adults presenting with numerous, large lesions and minimal conjunctival inflammation, consider evaluation for underlying immunocompromise. (moderate evidence) 2

Contact‑sport athletes should receive active lesion removal to prevent transmission – recommended by the American Academy of Pediatrics based on a 2017 pediatric study. 4
Patients or parents who wish to shorten the infection course may opt for active treatment – supported by the same 2017 pediatric evidence. 4

Incision and curettage (or simple excision with cautery) reliably eliminates lesions, lowers viral load, and enables the host immune system to clear residual virus; the technique must be aggressive enough to produce bleeding for complete removal – Level I evidence from a 2019 Ophthalmology study. 5
When multiple lesions are present, identifying and treating early (nascent) lesions reduces the risk of recurrence – emphasized in the 2019 Ophthalmology data. 5
Cryotherapy with liquid nitrogen provides cure rates comparable to 10 % potassium hydroxide in children, but carries a higher risk of post‑inflammatory hyperpigmentation or scarring, especially in patients with darker skin tones – evidence from a 2017 pediatric trial (Level II). 4

10 % potassium hydroxide is effective for cosmetically bothersome lesions or in patients with atopic dermatitis, achieving cure rates similar to cryotherapy in pediatric studies – Level II evidence from the 2017 Pediatrics report. 4
Cantharidin shows efficacy in open‑label and observational studies; a small randomized trial (n ≈ 30) did not reach statistical significance versus placebo, indicating modest benefit – Level II evidence from the 2017 pediatric literature. 4

Imiquimod does not improve outcomes compared with placebo in randomized controlled trials and should be avoided when evidence‑based therapy is required – Level I negative evidence from the 2017 Pediatrics trial. 4

Adults with numerous large, minimally inflamed lesions should be screened for immunocompromise (e.g., HIV infection, organ transplantation); severe or recalcitrant disease may necessitate cidofovir, interferon, or other systemic agents – recommendation derived from the 2019 Ophthalmology study (expert consensus, Level III). 5

Routine follow‑up is only indicated if conjunctivitis develops or if lesions persist after the chosen treatment – guidance from the 2019 Ophthalmology publication (Level II). 5

For immunocompetent children and adults: choose among curettage, cryotherapy (avoid in darker skin without counseling), 10 % potassium hydroxide, cantharidin, or FDA‑approved berdazimer gel (not cited). Evidence supporting these options comes from both the 2019 Ophthalmology and 2017 Pediatrics studies. [5][4]
For athletes in contact sports: lesions should be removed (preferably by curettage) before competition to limit transmission. 4
For immunocompromised patients: consider antiviral or immunomodulatory therapies such as cidofovir or interferon, with specialist referral. 5